RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, per interim data.

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for ...

US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...

(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

The company is advancing its diabetic retinopathy program into a pivotal stage, with plans for future BLA filings for RGX-202 for Duchenne Muscular Dystrophy and ABBV-RGX-314 for Wet AMD.

"RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial. The new data from the age 1-3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...